Predictive Clinical and Biological Parameters in Gynecological Cancer

Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01977274

Acronym

GC-BIO

Enrollment

300

Registered

2013-11-06

Start date

2013-12-01

Completion date

2035-12-01

Last updated

2026-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervix Cancer, Endometrium Cancer, Ovarian Cancer

Keywords

ovarian, endometrium, cervix cancer

Brief summary

Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation

Interventions

OTHERgynecological cancer

blood and tumor samples

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* gynecological cancer suspicion * age \> 18 * signed informed consent

Exclusion criteria

\- emergency

Design outcomes

Primary

Measure	Time frame	Description
molecular alteration in gynecological cancer	average of 4 weeks after diagnosis	gene expression level

Secondary

Measure	Time frame	Description
relation between molecular alteration and clinical and histological characteristics	up to 10 years	hazard ratio between molecular alteration and clinico-histological characteristics

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026